Lite Strategy (LTS:0JW9) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JW9 Lite Strategy Inc LTS:0JW9
44 GF Score
Price $0.93
GF Value $6.98
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Lite Strategy FFO per Share?

FFO per Share only applies to REITs.

LTS:0JW9
44GF Score
Lite Strategy Inc LTS:0JW9
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lite Strategy (LTS:0JW9) Overvalued in 2026?

Based on GuruFocus' analysis, Lite Strategy stock appears to be undervalued. The current stock price of $0.93 is trading 86.7% below its estimated GF Value™ of $6.98. GuruFocus considers Lite Strategy to be Possible Value Trap.

Key valuation signals for LTS:0JW9:

  • FFO per Share:
  • GF Value™: $6.98 vs. price of $0.93 (86.7% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the LTS:0JW9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lite Strategy Business Description

Other Exchanges LITS:USA
Address 9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
44GF Score

Get the complete analysis for LTS:0JW9

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price
$6.98
GF Value